- Pharmacia Australia Pty Ltd
SummaryPfizer Inc proposed to acquire Pharmacia Corporation. In Australia this will result in a merger between Pfizer Pty Limited and Pharmacia Australia Pty Limited and Pharmacia (Perth) Pty Limited.
Market definitionThe Commission analysed the impact of the merger on competition in a range of markets for human pharmaceutical products and products used for animal healthcare. In particular, the Commission focused on the market for cattle progesterone delivery devices (which are used by cattle breeders, veterinarians and farmers for the management of cattle reproduction) and the market for human erectile dysfunction treatments.
Competition analysisThe Commission was concerned that the worldwide merger may result in a substantial lessening of competition in Australia in relation to cattle progesterone products. In this context, the Commission accepted a court-enforceable undertaking from Pfizer Pty Ltd and Pfizer Overseas Inc to divest its CueMate product and business to a viable competitor, in order to address these concerns.
The undertaking, which requires Pfizer to divest its CueMate product, aims to preserve competition between two key products used for the treatment of non-cycling cows and synchronisation of the mating of multiple cows.
Whilst the Commission also had concerns in relation to the erectile dysfunction market the undertakings which have been given by the parties to the European Commission are considered sufficient to address the concerns for the Australian market. This involves the transfer of two products Pharmacia has in development: the dopamine D2 receptor (PNU-142774E) and Apomorphine hydrochloride nasal spray, which is being developed by Pharmacia in cooperation with Nastech Pharmaceutical Company, Inc.
Imports above 10%